C-Kit receptor and tryptase expressing mast cells correlate with angiogenesis in breast cancer patients

Ilaria Marech1, Michele Ammendola2, Christian Leporini3, Rosa Patruno4, Maria Luposella5, Nicola Zizzo6, Giuseppe Passantino4, Rosario Sacco2, Ammad Ahmad Farooqi6, Valeria Zuccalà7, Silvana Leo8, Rosalba Dentamaro9, Mariangela Porcelli1, Pietro Gadaletta1, Giovambattista De Sarro5, Cosmo Damiano Gadaletta1 and Girolamo Ranieri1

1Interventional and Medical Oncology Unit, National Cancer Research Centre, Istituto Tumori Giovanni Paolo II, 70124 Bari, Italy
2Department of Medical and Surgery Science Medical School, Clinical Surgery Unit, Magna Graecia University, 88100 Catanzaro, Italy
3Department of Health Science, Clinical Pharmacology and Pharmacovigilance Unit, Pharmacovigilance’s Centre Calabria Region, Magna Graecia University, Germaneto, 88100 Catanzaro, Italy
4Chair of Pathology, Veterinary Medical School, Aldo Moro University, 70010 Valenzano, Italy
5Cardiovascular Disease Unit, San Giovanni di Dio Hospital, 88900 Crotone, Italy
6Laboratory for Translational and Personalized Medicine, Rashid Latif Medical College, University of Lahore, 44000 Islamabad, Pakistan
7Pathology Unit, Pugliese-Ciaccio Hospital, 88100 Catanzaro, Italy
8Medical Oncology Unit, Vito Fazzi Hospital, Piazzetta Muratore, 73100 Lecce, Italy
9Senology Unit, National Cancer Research Centre, Istituto Tumori Giovanni Paolo II, 70124 Bari, Italy

Correspondence to: Girolamo Ranieri, email: giroran@tiscali.it

Keywords: C-Kit receptor; tryptase; mast cells; angiogenesis; breast cancer

Received: March 21, 2017  Accepted: October 28, 2017  Published: December 22, 2017

Copyright: Marech et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

C-Kit protein is a transmembrane tyrosine kinase (TK) receptor (c-KitR-TK), which is predominantly expressed on mast cells (MCs) playing a role in tumor angiogenesis. It could be also expressed on epithelial breast cancer cells (EBCCs), but no data have been published regarding the correlation between mast cells positive to c-KitR (MCs-c-KitR), EBCCs positive to c-KitR (EBCCs-c-KitR), BC angiogenesis in terms of microvessel density (MVD) and the main clinic-pathological features. This study aims to evaluate the above parameters and their correlations in a series of selected 121 female early BC patients. It has been found a strong correlation between MVD and MCDPT, and MCs-c-KitR, MVD and MCs density positive to tryptase (MCDPT), and MCs-c-KitR and MCDPT by Pearson correlation. These data suggest an involvement of both MCDPT and MCs-c-KitR in BC tumor angiogenesis. Furthermore, BC tissue expressing c-KitR could be a putative predictive factor to c-KitR-TK inhibitors. In this way, selected patients with higher MCs-c-KitR could be candidate to receive c-KitR-TK inhibitors (e.g. masitinib, sunitinib) or tryptase inhibitors (e.g. nafamostat mesilate, gabexate mesilate).

INTRODUCTION

C-KitR is the transmembrane tyrosine kinase (TK) receptor (c-KitR-TK) for stem cell factor (SCF), a cytokine regulating important functions of MCs such as proliferation and degranulation that in turn stimulate angiogenesis [1, 2]. C-KitR could be expressed also in other stromal cells, such as myofibroblasts and adipocyte cells, and epithelial breast cancer cells (EBCCs) stimulating proliferation. Several published studies showed that EBCCs positive to c-KitR (EBCCs-c-KitR) are low (from 10% to 29%) or absent in invasive breast cancer (IBC) [3–11]. In agreement, a progressive decrease and almost complete loss of EBCCs-c-KitR have been reported during the progression of normal tissue to BC [7, 8, 11–13]. Furthermore, EBCCs-c-KitR...
have been reported to be associated with more indolent cancer behavior [3, 6]. However, a small body of evidence suggests that EBCCs-c-KitR might represent an independent negative prognostic factor [4, 5, 10, 14–17]. Notably, c-KitR overexpression in IBC appeared to be an indicator of high-grade cancer resulting in poor prognosis [18]. This evidence suggests that c-KitR expression may play a role in BC progression. C-KitR expression has been also found increased in malignant breast phyllodes tumors (BPT), uncommon stromalepithelial lesions with different potential of malignancy [7, 8, 19–25]. For what concern the role of EBCCs-c-KitR and tumor angiogenesis, very little data have been published and only one study explored the relationship between EBCCs-c-KitR and microvascular density (MVD) demonstrating a negative correlation [3]. With special regard to MCs positive to c-KitR (MCs-c-KitR), a lot of in vitro data demonstrated that MCs play a role in tumor angiogenesis [26–31]. In particular, MCs stimulate angiogenesis by several mechanisms including c-KitR activation leading to the release of a plethora of angiogenic factors, contained in their cytoplasmic secretory granules [32, 33]. Among them, the most powerful factor is tryptase [32, 34]. Tryptase, acting on the protease-activated receptor-2 (PAR-2) by its proteolytic activity, has angiogenic activity stimulating both human vascular endothelial and tumor cell proliferation in paracrine manner, helping tumor cell invasion and metastasis [30, 35]. In in vivo studies it has been also shown that MCs density positive to tryptase (MCDPT) is strongly related to angiogenesis in several animal and human malignancies [2, 28, 33, 36–50]. With concern to early BC patients, we already demonstrated a strong correlation between high serum tryptase levels before surgery (STLBS) and MVD, STLBS and MCDPT, MCDPT and MVD [40].

To the best of our knowledge, no data have been published regarding the correlation between EBCCs-c-KitR, MCs-c-KitR, BC angiogenesis and clinicopathological features. In the current study we aim to evaluate the primary tumor tissue status of the above parameters to perform any possible correlation to each other and with clinicopathological characteristics in a series of 121 female early BC patients. Adjacent normal breast tissue has been also evaluated in terms of MCDPT, MVD, MCs-c-KitR and normal breast epithelium-c-KitR (NBE-c-KitR) expression. Finally, difference between the all the evaluated parameters in tumor tissue and adjacent normal breast tissue has been also assessed.

**RESULTS**

Data obtained from tumor tissue using light microscopy and image analysis system (Quantimet500 Leica, Wetzlar, Germany) [33] show the following mean ± 1 s.d.: MCDPT 7.49±2.81 (Figure 1A), MVD 29.41 ± 6.63 (Figure 1B), MCs-c-KitR 8.75 ± 3.26 (Figure 1C) and EBCCs-c-KitR 32.98 ± 16.61 (Figure 1D) (Table 2). MCs appear as round or spheroidal cells with a diffuse cytoplasmic red staining using the anti-tryptase antibody and with a filiform peripheral cell membranous intense staining using the anti-c-KitR and a blue spheroidal central nucleus. MCs are found as scattered cells (Figure 1A) or as cluster formation near and around microvessels that sometimes showed several red blood cells in their lumens (Figure 1C). Furthermore, microvessels appear as red immunostained structures and often their lumen is visible using the anti-CD34 antibody (Figure 1B). With special reference to EBCCs, a part of them shows a red strong filiform membranous staining utilizing the anti-c-KitR antibody (Figure 1D).

With special regard to normal tissue [33] the evaluated parameters showing the following mean ± 1 s.d.: MCDPT 2.86 ± 1.24 (Figure 2A), MVD 12.38 ± 3.97 (Figure 2B), MCs-c-KitR 3.01 ± 1.57 (Figure 2C) and EBCCs-c-KitR 59.69 ± 27.35 (Figure 2D) (Table 2).

In normal tissue EBCCs show the red strong filiform membranous staining utilizing the anti-c-KitR antibody; interestingly the part of EBCCs negative to the same immunostaining represents the internal negative control (Figure 2C, 2D). Obtained data evaluated by t-test analysis show a significant difference between mean regarding tumor tissue vs normal tissue in terms of MCDPT (r = 0.001), MVD (p = 0.003) MCs-c-KitR (r = 0.001), EBCCs-c-KitR vs NBE-c-KitR (p = 0.02) as summarized in Table 2.

A significant correlation between MVD and MCs-c-KitR (r = 0.77, p = 0.001), MVD and MCDPT (r = 0.83, p = 0.000), and MCs-c-KitR and MCDPT (r = 0.94; p = 0.000) is found by Pearson correlation (Figure 3A). There is no correlation between EBCCs-c-KitR and MCDPT (r = 0.067, p = n.s.), MVD and EBCCs-c-KitR (r = 0.18, p = n.s.), MCs-c-KitR and EBCCs-c-KitR (r = 0.042; p = n.s.) by Pearson test (Figure 3B).

**DISCUSSION**

C-KitR, also known as CD-117 (according to cluster differentiation nomenclature) is the receptor for SCF, a cytokine regulating important functions of MCs such as proliferation and degranulation that in turn stimulate angiogenesis [1, 2]. In particular, c-KitR-mediated MCs activation has been shown to induce tumor angiogenesis by the release of tryptase, the most powerful pro-angiogenic factor stored in MCs granules. In a preclinical model tryptase induces in vitro endothelial cells (ECs) proliferation in a matrigel assay and displayed in vivo capillary growth in the chick embryo chorioallantoic membrane, which was suppressed by tryptase inhibitors. In addition, tryptase can act on PAR-2 that can be expressed on epithelial cells stimulating cell proliferation of cancer cells in paracrine manner, potentiating invasion and metastasis [27–32, 51].
In vivo studies indicate that MCDPT is strongly related to angiogenesis in several malignancies [28, 33, 36–41]. In particular, pilot data suggest that MCDPT play a role in early BC angiogenesis [52]. Results from Ribatti et al. demonstrated that MCDPT contribute to angiogenesis leading to lymph nodes micrometastases in BC patients [53]. In agreement with the above literature, we have already demonstrated an involvement

Table 1: MCDPT, MVD, MCs-c-KitR and EBCCs-c-KitR as a function of clinico-pathological characteristics in a series of 121 breast cancer patients

| Variable                        | No. of patients | No. of tumours with high MCDPT\(^a\) (%) | No. of tumours with high MCs-c-KitR\(^b\) (%) | No. of tumours with high EBCCs-c-KitR\(^c\) (%) | No. of tumours with high STLBS \(^{**}\) (%) |
|---------------------------------|-----------------|------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| Age, years                      |                 |                                          |                                             |                                             |                                             |
| Range 26–87                     | 121             |                                           |                                             |                                             |                                             |
| Median 57                       |                 |                                           |                                             |                                             |                                             |
| < 57 years                      | 56              | 29 (52)                                  | 30 (54)                                    | 33 (59)                                    | 27 (48)                                    | 26 (55)                                    |
| ≥ 57 years                      | 65              | 37 (57)                                  | 34 (52)                                    | 32 (49)                                    | 33 (51)                                    | 31 (54)                                    |
| Menopausal status               |                 |                                          |                                             |                                             |                                             |                                             |
| Premenopausal                   | 51              | 28 (55)                                  | 24 (47)                                    | 27 (53)                                    | 29 (57)                                    | 23 (53)                                    |
| Postmenopausal                  | 70              | 38 (54)                                  | 37 (53)                                    | 39 (56)                                    | 34 (49)                                    | 32 (52)                                    |
| Hystological type               |                 |                                          |                                             |                                             |                                             |                                             |
| Ductal                          | 88              | 40 (45)                                  | 47 (53)                                    | 43 (49)                                    | 44 (50)                                    | 38 (49)                                    |
| Lobular                         | 33              | 17 (52)                                  | 16 (48)                                    | 15 (45)                                    | 19 (58)                                    | 13 (48)                                    |
| Tumour size                     |                 |                                          |                                             |                                             |                                             |                                             |
| pT\(_1\)                        | 67              | 36 (54)                                  | 32 (48)                                    | 35 (52)                                    | 33 (49)                                    | 27 (55)                                    |
| pT\(_2\)                        | 36              | 17 (47)                                  | 20 (56)                                    | 18 (50)                                    | 19 (53)                                    | 18 (51)                                    |
| pT\(_3\)                        | 18              | 8 (44)                                   | 9 (50)                                     | 10 (56)                                    | 9 (50)                                     | 10 (50)                                    |
| Nodal status                    |                 |                                          |                                             |                                             |                                             |                                             |
| pN\(_0\)                        | 52              | 23 (44)                                  | 25 (48)                                    | 28 (54)                                    | 24 (46)                                    | 20 (46)                                    |
| pN\(_1-2\)                      | 69              | 34 (49)                                  | 37 (54)                                    | 33 (48)                                    | 31 (45)                                    | 33 (54)                                    |
| Cytohistological grade          |                 |                                          |                                             |                                             |                                             |                                             |
| G\(_1\)                         | 42              | 23 (55)                                  | 19 (45)                                    | 21 (50)                                    | 22 (52)                                    | 21 (58)                                    |
| G\(_2\)                         | 51              | 24 (47)                                  | 23 (45)                                    | 25 (49)                                    | 24 (47)                                    | 21 (47)                                    |
| G\(_3\)                         | 28              | 16 (57)                                  | 13 (46)                                    | 15 (54)                                    | 12 (43)                                    | 11 (50)                                    |
| Estrogen receptor status        |                 |                                          |                                             |                                             |                                             |                                             |
| Negative                        | 32              | 17 (53)                                  | 18 (56)                                    | 14 (44)                                    | 19 (59)                                    | 13 (46)                                    |
| Positive                        | 89              | 44 (49)                                  | 47 (53)                                    | 48 (54)                                    | 42 (47)                                    | 36 (48)                                    |
| Progesteron receptor status     |                 |                                          |                                             |                                             |                                             |                                             |
| Negative                        | 38              | 19 (50)                                  | 16 (42)                                    | 18 (47)                                    | 21 (55)                                    | 18 (53)                                    |
| Positive                        | 83              | 36 (43)                                  | 37 (45)                                    | 39 (47)                                    | 45 (54)                                    | 39 (55)                                    |
| c-erbB-2 status                 |                 |                                          |                                             |                                             |                                             |                                             |
| Negative                        | 84              | 37 (44)                                  | 44 (52)                                    | 45 (54)                                    | 40 (48)                                    | 35 (51)                                    |
| Positive                        | 37              | 22 (59)                                  | 20 (54)                                    | 16 (43)                                    | 17 (6)                                     | 19 (52)                                    |

\(^a\)Median cut-off value: 7 cells per 400 field.
\(^b\)Median cut-off value: 29 microvessels per 400 field.
\(^c\)Median cut-off value: 8 cells per 400 field.
\(^d\)Median cut-off value: 31 cells per 400 field.
of increased circulating tryptase and MCDPT in BC angiogenesis [40].

With special regard to IBC, several evidences suggested that EBCCs-c-KitR are low (from 10% to 29%) or absent [3–11]. Consistently, a progressive decrease and almost complete loss in EBCCs-c-KitR have been showed during the progression of normal tissue to BC [11–13]. In fact, c-KitR is expressed by non-malignant epithelial rather than malignant epithelial breast tissue employing immunohistochemistry [7, 8]. Furthermore, EBCCs-c-KitR are related to a more indolent cancer behavior: high disease free survival, low grading, metastatic lymph nodes negative, receptor (ER, PgR, HER2neu) positive status [3, 6]. Conversely, some studies demonstrated that EBCCs-c-KitR may represent an independent factor of poor prognosis [5], as they are associated with receptor (ER, PgR, HER2neu) negative status, basal-like phenotype, BRCA1 mutation, positive metastatic lymph nodes positive, high grading, ki67 and mitotic index [4, 10, 14–17]. Of note, Kondi-Pafiti et al. observed that EBCCs-c-KitR are decreased in IBC and they appeared to be a marker of high-grade IBC, correlating with poor prognosis [18]. In particular it has been demonstrated that c-KitR may be expressed in breast myoepithelial cells and

**Figure 1:** (A) Breast cancer tissue sections evaluated by immunohistochemistry with the primary anti-tryptase antibody. Big arrows indicate single scattered red immunostained tryptase-positive mast cells, small arrows indicate single microvessels with red blood cells in theirs lumen and finally twice arrow indicates a cluster of breast cancer cells. Original magnification: x 400. (B) Breast cancer tissue sections evaluated by immunohistochemistry with the primary anti-CD34 antibody. Big arrows indicate single scattered red immunostained microvessel, small arrow indicates a cluster of red immunostained microvessels and finally twice arrow a cluster of breast cancer cells. Original magnification: x 400. (C) Breast cancer tissue sections evaluated by immunohistochemistry with the primary anti-cKitR antibody. Big arrows indicate single scattered red immunostained c-KitR positive mast cells with a well evident membranous staining. Small arrows indicate single microvessels with red blood cells in theirs lumen. Original magnification: x 400. (D) Breast cancer tissue sections evaluated by immunohistochemistry with the primary anti-cKitR antibody. Many red immunostained epithelial breast cancer cells positive to c-KitR. Big arrows indicate a well evident positive c-KitR membranous staining. Original magnification: x 400.
sometimes in some macrophages and smooth muscle cells of vascular walls. Amin et al. evaluated the relationship between EBCCs-c-KitR and microvascular density (MVD), showing that the loss of EBCCs-c-KitR is associated with high MVD and some markers of tumor aggressiveness (higher tumor grade, larger size, and more lymph node metastasis) [3]. In this context there are no studies evaluating the correlation between c-KitR-MCs and MVD in BC patients. Therefore, we aimed at verifying the presence of a correlation between MCs-c-KitR and EBCCs-c-KitR, MCDPT, MVD to each other in 121 female early BC patients. Our results demonstrated a

|                      | MCDPT 400x magnification (0.19 mm² area) | MVD 400x magnification (0.19 mm² area) | MCs-c-KitR 400x magnification (0.19 mm² area) | EBCCs-c-KitR 400x magnification (0.19 mm² area) |
|----------------------|------------------------------------------|----------------------------------------|---------------------------------------------|-----------------------------------------------|
| **a** 7.49 ± 2.81    | **a** 29.41 ± 6.63                      | **a** 8.75 ± 3.26                      | **a** 32.98 ± 16.61                         |
| **a** 2.86 ± 1.24    | **a** 12.38 ± 3.97                      | **a** 3.01 ± 1.57                      | **a** 59.69 ± 27.35                         |
| t-test *p* = 0.001  | *p* = 0.003                              | *p* = 0.001                            | *p* = 0.02                                 |

*a*Mean ± 1 standard deviation.

**Table 2:** MCDPT, MVD, MCs-c-KitR and EBCCs-c-KitR means ± 1 standard deviations in a series of 121 breast cancer patients

**Figure 2:** (A) Breast normal tissue sections evaluated by immunohistochemistry with the primary anti-tryptase antibody. Big arrows indicate only two single scattered red immunostained tryptase-positive mast cells in all examined field. Small arrows indicate normal breast epithelial cells. Original magnification: x 400. (B) Breast normal tissue sections evaluated by immunohistochemistry with the primary anti-CD34 antibody. Big arrows indicate two single scattered red immunostained microvessels, small arrows indicate normal breast epithelial cells. Original magnification: x 400. (C) Breast normal tissue sections evaluated by immunohistochemistry with the primary anti-cKitR antibody. Big arrow indicates a single mast cell with the red filiform membranous staining and its central blue nucleus. Small arrows indicate normal breast epithelial cells negative to cKitR immunostaining. Twice arrow indicates two normal breast epithelial cells positive to cKitR immunostaining. Original magnification: x 400. (D) Breast normal tissue sections evaluated by immunohistochemistry with the primary anti-cKitR antibody. Big arrows indicate normal breast epithelial cells positive to cKitR immunostaining. Small arrow indicates a mast cell red immunostained. Original magnification: x 400.
Figure 3: (A) Correlation analysis between: MVD and MCs-c-KitR ($r = 0.77$, $p = 0.001$), MVD and MCDPT ($r = 0.83$, $p = 0.000$), and MCs-c-KitR and MCDPT ($r = 0.94$, $p = 0.000$). (B) Correlation analysis between: EBCCs-c-KitR and MCDPT ($r = 0.067$, $p = n.s.$), MVD and EBCCs-c-KitR ($r = 0.18$, $p = n.s.$), c MCs-c-KitR and EBCCs-c-KitR ($r = 0.042$, $p = n.s.$).
strong and significant correlation between MVD, MCs-c-KitR and MCDPT. With reference to this finding, it must be considered that the number of c-KitR expressing cells may be slightly greater than MCDPT in that several stromal cells (such as myoepithelial cells, macrophages and smooth muscle cells) can also result positive to c-KitR expression. Moreover, we observed a significant difference in terms of MCDPT, MVD, MCs-c-KitR, EBCCs-c-KitR vs NBE-c-KitR (\( p = 0.02 \)) in tumor tissue vs adjacent normal tissue.

Taken together, the above evidences confirm the involvement of both MC tryptase and MCs-c-KitR in BC tumor angiogenesis. Additionally, the lack of correlation between increased MVD and high percentage of EBCCs-c-KitR suggests that clones of malignant EBCCs positive to c-KitR probably are not involved in tumor angiogenesis. Therefore, c-KitR and tryptase expressing MCs could represent a novel surrogate angiogenic marker in BC patients. Finally, they could also be identified as a new potential anti-angiogenetic target for several c-KitR-TK inhibitors (e.g. masitinib, sunitinib) or tryptase inhibitors (e.g. nafamostat mesilate, gabexate mesilate).

**MATERIALS AND METHODS**

The clinico-pathological features of the patients are summarized in the Table 1. A series of 121 BC patients observed at the Clinical Surgery Unit of the “Magna Graecia” University of Catanzaro were selected. Biopsy specimens were collected from 121 female BC patients who had undergone BC surgery. Patients were selected accordingly the presence of a primary, invasive breast tumor (stage T1-T3), the presence or not of metastases in axillary lymph nodes (stage N0-N2), the absence of distant metastases (M0), the presence of unilateral breast cancer and the absence of previous or concomitant primary cancer. Patients were staged according to the International Union Against Cancer Tumor Node Metastasis (UICC-TNM) classification [31]. They not received neo-adjuvant therapies. Surgical treatment performed was either a modified radical mastectomy (44 patients in which the tumor had a diameter ≥ 3 cm) or a quadrantectomy with axillary lymphadenectomy. No patient was subjected to the investigation of sentinel lymph node. Following surgery, a course of 5–6 weeks of radiation therapy (77 patients) was performed. On the basis of clinico-pathological features patients were evaluated to receive adjuvant hormonal therapy or chemotherapy or both. Full ethical approval and signed consent from individual patients were obtained to conduct the study. The full name of ethics institutional committee review board that approved our study is: University Hospital Ethics Committee “Mater Domini”, Germaneto, Catanzaro, Italy.

The histological diagnosis was made on haematoxylineosin-stained slides and histopathological grading was performed according to the criteria described by Bloom and Richardson, as well, moderately and poorly differentiated state [32]. For the evaluation of MCDPT, MVD, MCs-c-KitR and EBCCs-c-KitR a three-layer biotin-avidin-peroxidase system was utilized [33]. Briefly, six-μm-thick serial sections of formalin-fixed and paraffin-embedded of tumor tissue and adjacent normal breast tissue were cut. Then, sections were microwaved at 500 W for 10 min, after which endogenous peroxidase activity was blocked with 3% hydrogen peroxide solution. Adjacent sections were stained with human-specific monoclonal antibodies anti-tryptase (clone AA1; Dako, Glostrup, Denmark) diluted 1:100 for 1 h at room temperature, with anti-CD34 (QB-END 10; Bio-Optica Milan, Italy) as pan-endothelial marker diluted 1:50 for 1 h at room temperature and with the rabbit polyclonal antibodies anti-CD117 to c-KitR (Dako, Glostrup, Denmark) diluted 1:100 for 1 h at room temperature [2]. The bound antibody was visualized using a biotinylated secondary antibody, avidin-biotin peroxidase complex and fast red. Nuclear counterstaining was performed with Gill’s haematoxylin no. 2 (Polysciences, Warrington, PA, USA). The primary antibody was omitted in negative controls.

An image analysis system (Quantimet500 Leica, Wetzlar, Germany) was utilized [33]. For tumor tissue the five areas with higher immunostaining (‘hot spots’) were selected at low magnification and individual MCDPT (Figure 1A), MVD (Figure 1B), MCs-c-KitR (Figure 1C) and EBCCs-c-KitR (Figure 1D) were counted at ×400 magnification (0.19 mm² area).

With special reference to MVD, each microvessel was defined as single brown stained endothelial cells, endothelial cell clusters and microvessels, clearly separated from adjacent microvessels, tumor cells and other connective tissue elements were counted [54]. In the same manner, in adjacent normal tissue the five areas with higher immunostaining (‘hot spots’) were selected at low magnification and individual MCDPT (Figure 2A), MVD (Figure 2B), MCs-c-KitR (Figure 2C) and NBE-c-KitR (Figure 2D) were counted at ×400 magnification (0.19 mm² area).

MCDPT, MVD, MCs-c-KitR, EBCCs-c-KitR and NBE-c-KitR mean values ±1 standard deviation (s.d.) were evaluated by two independent observers (V.Z. and G.R.) for each tumor sample and in all series of sections (Table 2). Correlations between MCDPT, MVD, MCs-c-KitR and EBCCs-c-KitR were calculated using Pearson’s (r) analysis (Figure 3A, 3B). Difference between mean regarding tumor tissue vs normal tissue in terms of MCDPT (\( p = 0.001 \)), MVD (\( p = 0.003 \)) MCs-c-KitR (\( p = 0.001 \)), EBCCs-c-KitR vs NBE-c-KitR (\( p = 0.02 \)) was evaluated by t-test analysis. Obtained data evaluated by t-test analysis show a significant difference between mean regarding tumor tissue vs normal tissue in terms of MCDPT (\( p = 0.001 \)), MVD (\( p = 0.003 \)) MCs-c-KitR (\( p = 0.001 \)), EBCCs-c-KitR (\( p = 0.02 \)) as summarized in Table 2.
The correlations between the above indexes and the clinico-pathological features listed in Table 1 were analyzed by the Chi-square test. All statistical analyses were performed with the SPSS statistical software package (SPSS, Inc., Chicago, IL).

**Author contributions**

IM and GR designed the study, conducted experiments, analyzed and interpreted data and wrote the manuscript. MA, NZ, GP, RS, MP, GDS, and CDG ensured protocol integrity and collected data. MA, NZ, VZ, PG, RP, and ML conducted experiments and collected data. IM, MA, CL, AAF, SL, RD, and GDS analyzed and interpreted data. All authors reviewed the manuscript. All authors read and approved the final manuscript.

**ACKNOWLEDGMENTS**

This work was supported by a grant of “Fondi della Ricerca Corrente 2016” assigned to Istituto Tumori “Giovanni Paolo II” (Bari) dished out by the Italian Ministry of Health.

**CONFLICTS OF INTEREST**

The authors confirm that there are no conflicts of interest.

**REFERENCES**

1. Kitamura Y, Hirotab S. Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci. 2004; 61:2924–2931.
2. Patruno R, Marech I, Zizzo N, Ammendola M, Nardulli P, Gadaleta C, Introna M, Capriuolo G, Rubini RA, Ribatti D, Gadaleta CD, Ranieri G. c-Kit expression, angiogenesis, and grading in canine mast cell tumour: a unique model to study c-Kit driven human malignancies. Biomed Res Int. 2014; 2014:730246.
3. Amin MM, El-Hawary AK, Farouk O. Relation of CD117 immunoreactivity and microvascular density in invasive breast carcinoma. Indian J Pathol Microbiol. 2012; 55:456–460.
4. Kashiwagi S, Yashiro M, Takashima T, Aomatsu N, Kawajiri H, Ogawa Y, Onoda N, Ishikawa T, Wakasa K, Hirakawa K. c-Kit expression as a prognostic molecular marker in patients with basal-like breast cancer. Br J Surg. 2013; 100:490–496.
5. Charpin C, Giusiano S, Charfi S, Secq V, Carpentier S, Andrac L, Lavaut MN, Allasia C, Bonnier P, Garcia S. Quantitative immunohistochemical expression of c-Kit in breast carcinomas is predictive of patients’ outcome. Br J Cancer. 2009; 101:48–54.
6. Tsutsui S, Yasuda K, Suzuki K, Takeuchi H, Nishizaki T, Higashi H, Era S. A loss of c-kit expression is associated with an advanced stage and poor prognosis in breast cancer. Br J Cancer. 2006; 94:1874–1878.
7. Yared MA, Middleton LP, Meric F, Cristofanilli M, Sahin AA. Expression of c-kit proto-oncogene product in breast tissue. Breast J. 2004; 10:323–327.
8. Chui X, Egami H, Yamashita J, Kurizaki T, Ohmachi H, Yamamoto S, Ogawa M. Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues. Br J Cancer. 1996; 73:1233–1236.
9. Crisi GM, Marconi SA, Makari-Judson G, Goulart RA. Expression of c-kit in adenoid cystic carcinoma of the breast. Am J Clin Pathol. 2005; 124:733–739.
10. Tsuda H, Morita D, Kimura M, Shinto E, Ohtsuka Y, Matsubara O, Inazawa J, Tamaki K, Mochizuki H, Tamai S, Hiraike H. Correlation of KIT, EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation. Cancer Sci. 2005; 96:48–53.
11. Talaei-Zadeh A, Jazayeri SN, Nateghi J. Expression of c-kit protein in cancer vs. normal breast tissue. Contemp Oncol (Pozn). 2012; 16:306–309.
12. Ulivi P, Zoli W, Medri L, Amadori D, Saragoni L, Barbanti F, Calistri D, Silvestrini R. c-kit and SCF expression in normal and tumor breast tissue. Breast Cancer Res Treat. 2004; 83:33–42.
13. Ko CD, Kim JS, Ko BG, Son BH, Kang HJ, Yoon HS, Cho EY, Gong G, Ahn SH. The meaning of the c-kit proto-oncogene product in malignant transformation in human mammary epithelium. Clin Exp Metastasis. 2003; 20:593–597.
14. Kanapathy Pillai SK, Tay A, Nair S, Leong CO. Triple-negative breast cancer is associated with EGFR, CK5/6 and c-KIT expression in Malaysian women. BMC Clin Pathol. 2012; 12:18.
15. Regan JL, Kendrick H, Magnay FA, Vafaizadeh V, Groner B, Smalley MJ. c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer. Oncogene. 2012; 31:869–883.
16. Smart CE, Wronski A, French JD, Edwards SL, Asselin-Labat ML, Waddell N, Peters K, Brewster BL, Brooks K, Simpson K, Manning N, Lakhani SR, Grimmond S, et al. Analysis of Brca1-deficient mouse mammary glands reveals reciprocal regulation of Brca1 and c-kit. Oncogene. 2011; 30:1597–1607.
17. Nalwoga H, Arnes JB, Wabinga H, Akslen LA. Expression of EGFR and c-kit is associated with the basal-like phenotype in breast carcinomas of African women. APMIS. 2008; 116:515–525.
18. Kondi-Pafiti A, Arkadopoulos N, Gennatas C, Michalaki V, Frangou-Plegmenou M, Chatziplantelis P. Expression of c-kit in common benign and malignant breast lesions. Tumori. 2010; 96:978–984.
19. Bose P, Dunn ST, Yang J, Allen R, El-Khoury C, Tafyal A. c-Kit expression and mutations in phyllodes tumors of the breast. Anticancer Res. 2010; 30:4731–4736.
20. Chen CM, Chen CJ, Chang CL, Shy JS, Hsieh HF, Harn HJ, CD34, CD117, and actin expression in phyllodes tumor of the breast. J Surg Res. 2000; 94:84–91.

21. Carvalho S, e Silva AO, Milanezi F, Ricardo S, Leitao D, Amendoceira I, Schmitt FC. c-KIT, PDGFRA in breast phyllodes tumours: overexpression without mutations? J Clin Pathol. 2004; 57:1075–1079.

22. Sawyer EJ, Poulsom R, Hunt FT, Jeffery R, Elia G, Ellis IO, Ellis P, Tomlinson IP, Hanby AM. Malignant phyllodes tumours show stromal overexpression of c-myc and c-kit. J Pathol. 2003; 200:59–64.

23. Tan PH, Jayabaskar T, Yip G, Tan Y, Hilmy M, Selvarajan S, Bay BH. p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study. Mod Pathol. 2005; 18:1527–1534.

24. Tse GM, Putti TC, Lui PC, Lo AW, Scolyer RA, Law BK, Karim R, Lee CS. Increased c-kit (CD117) expression in malignant mammary phyllodes tumors. Mod Pathol. 2004; 17:827–831.

25. Tan WJ, Thike AA, Tan SY, Tse GM, Tan MH, Bay BH, Tan PH. CD117 expression in breast phyllodes tumors correlates with adverse pathologic parameters and reduced survival. Mod Pathol. 2015; 28:352–358.

26. Blair RJ, Meng H, Marchese MJ, Ren S, Schwartz LB, Tonnesen MG, Gruber BL. Human mast cells stimulate vascular tubule formation. Tryptase is a novel, potent angiogenic factor. J Clin Invest. 1997; 99:2691–2700.

27. Ribatti D, Ranieri G, Nico B, Benagiano V, Crivellato E. Tryptase and chymase are angiogenic in vivo in the chorioallantoic membrane assay. Int J Dev Biol. 2011; 55:99–102.

28. Ribatti D, Guidolin D, Marzullo A, Nico B, Annese T, Benagiano V, Crivellato E. Mast cells and angiogenesis in gastric carcinoma. Int J Exp Pathol. 2010; 91:350–356.

29. Passantino L, Passantino G, Cianciotta A, Ribaud MR, Lo Presti G, Ranieri G, Perillo A. Expression of proto-oncogene C-kit and correlation with morphological evaluations in canine cutaneous mast cell tumors. Immunopharmacol Immunotoxicol. 2008; 30:609–621.

30. Ammendola M, Leporini C, Marech I, Gadaleta CD, Scognamiglio G, Sacco R, Sammarco G, De Sarro G, Russo E, Ranieri G. Targeting Mast Cells Tryptase in Tumor Microenvironment: A Potential Antiangiogenic Strategy. Biomed Res Int. 2014; 2014:154702.

31. Stack MS, Johnson DA. Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase). J Biol Chem. 1994; 269:9416–9419.

32. Ribatti D, Ranieri G. Tryptase, a novel angiogenic factor stored in mast cell granules. Exp Cell Res. 2015; 332:157–162.

33. Marech I, Gadaleta CD, Ranieri G. Possible Prognostic and Therapeutic Significance of c-KIT Expression, Mast Cell Count and Microvessel Density in Renal Cell Carcinoma. Int J Mol Sci. 2014; 15:13060–13076.
patients undergone to surgery. Expert Opin Ther Targets. 2016; 20:533–540.

45. Leporini C, Ammendola M, Marchi I, Sammarco G, Sacco R, Gadaleta CD, Oakley C, Russo E, De Sarro G, Ranieri G. Targeting mast cells in gastric cancer with special reference to bone metastases. World J Gastroenterol. 2015; 21:10493–10501.

46. Ranieri G, Ammendola M, Marchi I, Laterza A, Abbate I, Oakley C, Vacca A, Sacco R, Gadaleta CD. Vascular endothelial growth factor and tryptase changes after chemoembolization in hepatocarcinoma patients. World J Gastroenterol. 2015; 21:6018–6025.

47. Ammendola M, Marchi I, Sammarco G, Zuccala V, Luposella M, Zizzo N, Patruno R, Crovace A, Ruggieri E, Zito AF, Gadaleta CD, Sacco R, Ranieri G. Infiltrating mast cells correlate with angiogenesis in bone metastases from gastric cancer patients. Int J Mol Sci. 2015; 16:3237–3250.

48. Ranieri G, Pantaleo M, Piccinino M, Roncetti M, Mutinati M, Marchi I, Patruno R, Rizzo A, Sciorsci RL. Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: a comparative review. Crit Rev Oncol Hematol. 2013; 88:293–308.

49. Ranieri G, Passantino L, Patruno R, Passantino G, Jirillo F, Catin A, Mattioli V, Gadaleta C, Ribatti D. The dog mast cell tumour as a model to study the relationship between angiogenesis, mast cell density and tumour malignancy. Oncol Rep. 2003; 10:1189–1193.

50. Ranieri G, Marchi I, Pantaleo M, Piccinino M, Roncetti M, Mutinati M, Rizzo A, Gadaleta CD, Introna M, Patruno R, Sciorsci RL. In vivo model for mastocytosis: A comparative review. Crit Rev Oncol Hematol. 2015; 93:159–169.

51. Xiang M, Gu Y, Zhao F, Lu H, Chen S, Yin L. Mast cell tryptase promotes breast cancer migration and invasion. Oncol Rep. 2010; 23:615–619.

52. Ranieri G, Ammendola M, Patruno R, Celano G, Zito FA, Montemurro S, Rella A, Di Lecce V, Gadaleta CD, Battista De Sarro G, Ribatti D. Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients. Int J Oncol. 2009; 35:115–120.

53. Ribatti D, Finato N, Crivellato E, Guidolin D, Longo V, Mangieri D, Nico B, Vacca A, Beltrami CA. Angiogenesis and mast cells in human breast cancer sentinel lymph nodes with and without micrometastases. Histopathology. 2007; 51:837–842.

54. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med. 1991; 324:1–8.